首次人体评估[18F]AldoView:一种高选择性醛固酮合酶PET显像剂用于原发性醛固酮增多症
本研究在3名健康志愿者中评估[18F]AldoView的生物分布与辐射剂量学,并纳入15例肾上腺病变患者(13例原醛、1例库欣综合征、1例无功能腺瘤)行PET/CT。结果显示示踪剂耐受良好、无不良事件,有效剂量0.012±0.0022 mSv/MBq;10例原醛患者病灶阳性,平均SUVmax 15.73±8.57、病灶/肾上腺比值8.02±4.06、病灶/肝脏比值10.24±1.48,病理CYP11B2染色强阳性。
要点
- 3名健康志愿者全身PET/CT评估生物分布与剂量学,有效剂量0.012±0.0022 mSv/MBq。
- 15例肾上腺病变患者注射后60分钟行PET/CT,病灶摄取超过正常肾上腺组织判为阳性。
- 10例原醛患者病灶阳性,平均SUVmax 15.73±8.57,病理CYP11B2强染色证实为产醛固酮腺瘤或结节。
核心结论
- [18F]AldoView PET/CT对原醛患者产醛固酮腺瘤和结节显像安全、可行,结果突显其无创在体检测CYP11B2的潜力,支持用于原醛分型。
研究设计与样本
- 首次人体研究,在3名健康志愿者中用全身PET/CT评估[18F]AldoView的生物分布与剂量学。
- 纳入15例肾上腺病变患者(13例原醛、1例库欣综合征、1例无功能腺瘤),注射后60分钟行PET/CT。
- 病灶示踪剂摄取超过正常肾上腺组织判为阳性,并行SUVmax、病灶/肝脏比值和病灶/肾上腺比值半定量分析。
- 10例影像阳性的原醛患者和1例库欣综合征患者接受肾上腺切除术,切除标本分析CYP11B2表达。
- 该进行中的研究已在中国临床试验注册中心注册(ChiCTR2400093214)。
主要发现
- [18F]AldoView耐受良好,无不良事件,有效剂量为0.012±0.0022 mSv/MBq。
- PET/CT在全部10例原醛患者中识别出阳性病灶,平均SUVmax为15.73±8.57、病灶/肾上腺比值为8.02±4.06、病灶/肝脏比值为10.24±1.48。
- 特发性醛固酮增多症、库欣综合征和无功能腺瘤患者中未观察到阳性病灶。
- 阳性病灶病理显示CYP11B2强染色,证实为产醛固酮腺瘤或产醛固酮结节。
关键数值与推荐
- 病灶阳性判定标准为示踪剂摄取超过正常肾上腺组织。
- PET/CT扫描时间为注射后60分钟。
- 有效剂量为0.012±0.0022 mSv/MBq。
- 10例原醛患者平均SUVmax 15.73±8.57、病灶/肾上腺比值8.02±4.06、病灶/肝脏比值10.24±1.48。
临床怎么用
- 原文结论认为[18F]AldoView PET/CT对原醛患者产醛固酮腺瘤和结节显像安全、可行,支持其用于原醛分型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Aldosterone synthase (CYP11B2) is overexpressed in primary aldosteronism (PA), making it a promising target for imaging. This first-in-human study evaluates the safety and feasibility of [ 18 F]AldoView, a highly selective PET tracer targeting CYP11B2, for PA subtyping. METHODS: Biodistribution and dosimetry of [ 18 F]AldoView were assessed in 3 healthy volunteers using whole-body PET/CT. Fifteen patients with adrenal lesions (13 with PA, 1 with Cushing's syndrome, and 1 with a nonfunctional adenoma) were enrolled. PET/CT scans were performed 60 minutes postinjection. Lesions were considered positive if tracer uptake exceeded normal adrenal tissue. Semi-quantitative analyses included maximum standardized uptake value (SUVmax), lesion-to-liver ratio (LLR), and lesion-to-adrenal ratio (LAR). Ten PA patients with positive imaging findings and 1 with Cushing's syndrome underwent adrenalectomy, and resected specimens were analyzed for CYP11B2 expression. This ongoing study is registered with the Chinese Clinical Trial Registry (ChiCTR2400093214). RESULTS: [ 18 F]AldoView was well-tolerated, with no adverse events. The effective dose was 0.012±0.0022 mSv/MBq. PET/CT identified positive lesions in all 10 PA patients, with a mean SUVmax of 15.73±8.57, LAR of 8.02±4.06, and LLR of 10.24±1.48. No positive lesions were observed in patients with idiopathic hyperaldosteronism, Cushing's syndrome, or nonfunctional adenomas. Positive lesions showed strong CYP11B2 staining on pathology, confirming aldosterone-producing adenomas (APA) or nodules (APN). CONCLUSIONS: [ 18 F]AldoView PET/CT is safe and feasible for the imaging of APAs and APNs in PA patients. These results highlight its potential for noninvasive in vivo detection of CYP11B2, supporting its use in PA subtyping.
引用
- Long T, Liu G, Zhou M, et al. First-in-Human Evaluation of [ 18 F]AldoView: A Highly Selective PET Tracer for Aldosterone Synthase Imaging in Primary Aldosteronism. Clin Nucl Med. 2025. PMID: 40472250. doi:10.1097/RLU.0000000000006014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。